The Quantellect read.As of Nov 19, 2026, 3 active firms cover Sophia Genetics SA: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $7.00 to $14.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $10.00 sits 34% above the current $7.45. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$10.00
+34.2% upside
Average target across 3 active firms as of Nov 19, 2026 vs $7.45 current
Highest Target$14.00
Average Target$10.00
Lowest Target$7.00
Detailed analyst forecasts for SOPH
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate SOPH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SOPH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.18 – $-0.18 · 1 analysts · -6% YoY
Next period, 1 analysts expect Sophia Genetics SA to earn $-0.18 a share (range $-0.18 – $-0.18), versus $-0.19 a year earlier. Full-year consensus is $-0.88, growing to $-0.55 the year after.
REVENUE · NEXT QUARTER
$26.2M
Range $25.4M – $27.0M · 1 analysts · +21% YoY
Revenue is expected to reach $26.2M (range $25.4M – $27.0M), +20.7% year-over-year. Full-year consensus is $95.6M, rising to $118.8M next year.
Top analysts covering Sophia Genetics SA
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SOPH.
#1
Mark Massaro
BTIG · Rank #220
Buy
$9.00+20.8% to target
Overall win rate
44%
+ Follow
#2
Conor McNamara
RBC Capital · Rank #254
Buy
$7.00-6.0% to target
Overall win rate
34%
+ Follow
#3
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #321
Buy
$14.00+87.9% to target
Overall win rate
38%
+ Follow
#4
TS
Tejas Savant
Morgan Stanley
Neutral
$5.00-32.9% to target
Coverage
—
+ Follow
#5
WB
William Bonello
Craig-Hallum
Buy
No targeton SOPH
Coverage
—
+ Follow
SOPH stock forecast FAQ
What is SOPH's average 12-month price target?+
The 3 active firms with a live target average $10.00 for Sophia Genetics SA over the next 12 months, ranging from a $14.00 high to a $7.00 low, as of Nov 19, 2026.
Is SOPH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SOPH?+
The Street-high target is $14.00 (HC Wainwright & Co.), and the Street-low is $7.00 (Guggenheim). The average of all 3 active-firm targets is $10.00.
How many active Wall Street firms cover SOPH?+
3 active firms have a recognized rating on Sophia Genetics SA as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SOPH?+
Among analysts who currently cover SOPH, Mark Massaro of BTIG has the strongest overall Quantellect track record (Rank #220). Their current call is Buy with a $9.00 target.
What is Sophia Genetics SA's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.18 – $-0.18) across 1 analysts. Full-year EPS is projected at $-0.88, rising to $-0.55 the following year.
How much revenue is Sophia Genetics SA expected to report next quarter?+
Consensus revenue is $26.2M (range $25.4M – $27.0M). Full-year revenue is projected at $95.6M, growing to $118.8M next year.
Have analysts been upgrading or downgrading SOPH lately?+
As of Nov 19, 2026, 3 of 3 active firms rate SOPH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SOPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.